TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Muscle thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in parafoveal thickness (PFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trail Making Test A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digit Backwards Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gait Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Outcome Measures
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of annual self-directed deaths
Endpoint domain: Mortality/survival
Primary endpoint: Internalizing Symptoms Subscale of the Youth Self-Report
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in ADAS-Cog11 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Concentration of Troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of unplanned ED visits/hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resource utilisation in dementia
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Timed Up and Go (Cognitive)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative weekly opioid intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Activity limitation due to low back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number, type and frequency of DDR and MMR germline/somatic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in PSA levels in the 3 cohorts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk for colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Oral manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of weight in women of reproductive age before and after nutritional intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in BMI of women of reproductive age before and after nutritional intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in body composition of total fat and fat-free mass of women of reproductive age before and after nutritional intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC (Area Under the Receiver-Operating Characteristic [ROC] Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short form 36 Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: GlioStem frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour crystalloid intravenous fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Information seeking behavior
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area Under the Curve (AUC), Sensitivity, and Specificity of VCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyclosporine level concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-based dose for obese patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI as an anthropometric measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adenomas per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of Life measured by EQ-5D-5L EQ visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life measured by EQ-5D-5L EQ-5D descriptive system
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life measured by SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of autonomic dysfunction (sympathetic domain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of autonomic dysfunction (Para-sympathetic domain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: size of gastric pouch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leeds Assessment Neuropathic Symptoms and Signs (LANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Q-DASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ETCP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: active movements of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: GOALS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Errors
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients with AAO-HNS Vertigo Control Class A or B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Dizziness Between Treatment Arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Experiencing Significant Hearing Fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mEASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post-operative wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of risk reduction for chemotherapy
Endpoint domain: Mortality/survival
Primary endpoint: Prolonged survival time gain for chemotherapy
Endpoint domain: Mortality/survival
Primary endpoint: Health-related Quality of life (KIDSCREEN)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mental Health Literacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in airway smooth muscle biology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inflammatory measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mid-arm muscle area (MAMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Samples with DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Myocarditis and/or Pericarditis within 30 Days After Moderna vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Severe Clinical Outcomes Within 30 Days After Onset of Myocarditis or Pericarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Long Term Clinical Outcomes After Onset of Myocarditis and/or Pericarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Thrombotic Events (TEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With Acute kidney injury (AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Hemolytic Events (HEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of genetic determinants of macrolide resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in Global Cognitive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Physical Activity Distances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep quality duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mammogram Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evolution according to the WHO Clinical Progression Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary function test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grade of hyperkeratotic skin removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Perceived caregiver stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiver depressive and anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dynamic knee valgus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lateral trunk flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in activity in brain areas controlling the bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of non-criteria aPL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Griffiths Scales of Child Development, 3rd Edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication and Symbolic Behaviour Scales - Infant-Toddler Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of HER2-positive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants who are MRD negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cyst size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of INHBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sgACC response to the Incentive Flanker Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: airway microbiome/metabolome modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leptin levels and insulin sensitivity modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: changes in asthma biomarkers and clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Lung ultrasound score (LUSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overdenture retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of providers who indicate likelihood of using SECD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of interested patients who schedule an appointment to be screened
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Anti-HAV diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-HAV IgM diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Analyte Concentration versus Time Curve (AUC [0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Analyte Concentration versus Time Curve (AUC [0-Infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in responsive grip behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numerical rating scale (NRS) score 2 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numerical rating scale (NRS) score 8 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numerical rating scale (NRS) score 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of facial paralysis
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate Improvement at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serious Adverse Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Power spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Assessment Scale in Cancer Treatment (FACT-B)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lower limb pain responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CHANGE IN P/F
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CHANGE IN PaCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Treatment Failure for Lorlatinib as the Second Line Therapy and the Third or Later Line Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective contraceptive use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants with Emergence of Clinically Manifest ALS
Endpoint domain: Mortality/survival
Primary endpoint: Grade of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement on QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement on Sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: HPV cfDNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Activation of brain circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of dose limiting toxicities of enasidenib
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration versus time curve of enasidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma clearance of enasidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of enasidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of enasidenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with impactful finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of [U-13C]glucose incorporation into metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of [U-13C15N]L-glutamine incorporation into metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Initial Classification Accuracy Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability of treatment by clinical staff
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of treatment by families of DOC patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of positive delirium screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed-type hypersensitivity reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in score on the Symbol Digit Modality Test (SDMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Systemic tolerability and safety
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Posttraumatic Stress Disorder (PTSD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: End-of-study insulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance in Squat Jump Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in 30 meter sprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hand Hygiene Behavior scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Mask Usage Behavior scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients achieving ≥2 × 10ˆ6/kg CD34+ HSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ≥ 67% sustained reduction in the TB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard ratio for time to stable culture conversion (SCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrio-ventricular coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular arterial coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changed in pain scale from Day 0 to 12 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Total Antioxidant Capacity (TAC) in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Ascorbic Acid (AA) in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of treated lesions with device success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with RSV-related hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Cotinine-verified 7-day smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody positivity for A, C, Y and W135
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in overall mental and physical well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CIDP Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oxford Muscle Strength Score (Medical Research Council, MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vibration Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time 0 to Last Quantifiable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of MK-6552 in a Fasted State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-life (t1/2) of MK-6552 in a Fasted State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Disease Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Choline Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Global vocal performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cramp severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of lung volume distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variation of airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variation of esophageal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants achieving PPPASI-50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Daily Urinary Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Percentage of Time Spent in Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients experiencing a best corrected visual acuity (BCVA) ≥15-letter loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of hospital and/or ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of NIV and IMV/ECMO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of JR-446
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of JR-446
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes